文献速递睡眠呼吸障碍

持续气道正压通气治疗高危妊娠合并阻塞性睡眠呼吸暂停:一项Meta分析

Positive Airway Pressure Therapy for Obstructive Sleep Apnea in High-Risk Pregnancy: A Meta-Analysis.
PubMed 文献 · Laryngoscope · 2025-08-15

本Meta分析纳入7项研究共696例高危妊娠合并OSA患者,其中328例接受PAP治疗。PAP治疗与更低的空腹血糖(MD -6.50,95%CI -10.64至-2.36,p=0.002,I²=3.2%)和改善的胰岛素抵抗(HOMA-IR MD -0.90,95%CI -1.15至-0.65,p<0.01,I²=0%)相关,其他母婴结局无显著差异。作者认为PAP可能通过改善糖代谢相关母体结局使高危妊娠合并OSA患者获益,对其他母婴结局影响有限。

要点

  • PAP治疗与高危妊娠合并OSA患者空腹血糖降低相关(MD -6.50,95%CI -10.64至-2.36)。
  • PAP治疗与HOMA-IR降低相关(MD -0.90,95%CI -1.15至-0.65),提示胰岛素抵抗改善。
  • 其他母体及新生儿结局在PAP组与非PAP组间无显著差异。

核心结论

  • 作者认为PAP治疗可能通过改善糖代谢相关母体结局使高危妊娠合并OSA患者获益,对其他母婴结局影响有限。

研究设计与样本

  • 系统检索PubMed、Embase、Web of Science和Cochrane Library,纳入比较PAP治疗与无治疗或非PAP治疗(等候名单、假PAP、鼻扩张条)的研究。
  • 共纳入7项研究、696例高危妊娠合并OSA患者,其中328例接受PAP治疗。
  • 连续结局采用均数差(MD),二分类结局采用风险比(RR),均报告95%CI。

主要发现

  • PAP治疗与更低的空腹血糖相关(MD -6.50,95%CI -10.64至-2.36,p=0.002,I²=3.2%)。
  • PAP治疗与更低的HOMA-IR相关(MD -0.90,95%CI -1.15至-0.65,p<0.01,I²=0%),提示胰岛素抵抗改善。
  • 其他母体及新生儿结局(包括妊娠期糖尿病、血压、妊娠期高血压疾病、剖宫产、Epworth嗜睡量表、出生体重、1分钟和5分钟Apgar评分、早产、胎儿生长异常、新生儿重症监护室入院)未见显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to assess the effects of positive airway pressure (PAP) therapy in high-risk pregnancy patients with OSA. DATA SOURCES: Studies were systematically searched on PubMed, Embase, Web of Science, and Cochrane Library. REVIEW METHODS: Articles comparing PAP therapy to no treatment or non-PAP treatment modalities, such as waitlist, sham PAP, and nasal dilator strips in high-risk pregnancy patients with OSA were included. Outcomes of interest included fasting plasma glucose (FPG), estimated insulin resistance, gestational diabetes, blood pressure measurements, hypertensive disorders of pregnancy, cesarean section, Epworth Sleepiness Scale, birth weight, Apgar at 1 and 5 min, preterm delivery, fetal growth abnormalities, and neonatal intensive care unit admission. Mean difference (MD) was used for continuous outcomes and risk ratio for binary endpoints, with 95% confidence intervals (CI). RESULTS: Seven studies involving 696 patients were included, of which 328 patients were treated with PAP therapy. PAP therapy was associated with lower FPG (MD -6.50, 95% CI -10.64 to -2.36, p = 0.002, I 2 = 3.2%) and improved insulin resistance, as indicated by reduced HOMA-IR levels (MD -0.90, 95% CI -1.15 to -0.65, p < 0.01; I 2 = 0%). No significant differences were observed in other maternal or neonatal outcomes. CONCLUSION: Our findings suggest PAP therapy may benefit high-risk pregnant women with OSA by improving certain maternal outcomes related to glucose metabolism, while effects on other maternal and neonatal outcomes are limited.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Cabral TDD, Knoll RM, Plane J, et al. Positive Airway Pressure Therapy for Obstructive Sleep Apnea in High-Risk Pregnancy: A Meta-Analysis. Laryngoscope. 2025. PMID: 40815548. doi:10.1002/lary.70009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。